Abstract: Provided is a method of producing succinic acid in which a microorganism having a succinic acid-producing ability is allowed to react with a sugar, the method being characterized in that the ratio of the oxygen transfer rate to the succinic acid production rate (mmol-O2/mol-SA) is 0.1 to 240 and that the doubling time of the microorganism during the reaction is not shorter than 40 hours.

Abstract: The present invention relates to methods for the production of heat shock protein complexes for use in vaccine compositions. In particular, there is provided a method for increasing the level and immunogenicity of heat shock protein complexes produced in cells by subjecting the cells to specific stress inducing stimuli. The invention further extends to the use of heat shock protein complexes produced according to the methods of the invention in the preparation of vaccine compositions for the prevention and treatment of infectious diseases and cancerous conditions.

Abstract: The present invention provides a modified promoter DNA capable of enhancing transcription of genes encoding proteins or polypeptides, and a method for producing proteins or polypeptides efficiently by use of the modified promoter DNA. A promoter DNA recognized by SigA and SigE, which is produced by modifying a nucleotide sequence including a promoter recognized by SigA and bases in the vicinity thereof; an expression vector harboring the promoter DNA; a recombinant microorganism containing the expression vector; and a method for producing proteins or polypeptides characterized by culturing the recombinant microorganism.

Abstract: The present invention provides methods of producing isolated heat stable polypeptides by expressing the polypeptides in a prokaryotic host cell and subjecting the host cell to heat lysis. The invention further provides screening methods by producing a plurality of isolated heat stable polypeptides by expressing each of the plurality of polypeptides in a prokaryotic host cell and subjecting the host to heat lysis.

Abstract: An object of the present invention is to find a novel and useful component in a culture supernatant of a lactic acid bacterium and to provide an effective utilization method of the component. The utilization method is a cytoprotective agent containing, as an active ingredient, a low-molecular-weight fraction in a culture supernatant of a lactic acid bacterium belonging to Streptococcus thermophilus.

Abstract: Novel brazzein variants having higher sweetness and the use thereof are provided. The brazzein variants or multi-variants have higher sweetness than a wild-type brazzein protein. Also, a method of preparing the brazzein variants and a food composition for enhancing a sugar content including the same are provided. The brazzein variants or multi-variants have higher sweetness at least twice that of a conventional brazzein protein, and show equivalent properties such as thermal and pH stabilities and high water solubility compared to the conventional brazzein protein. Therefore, a smaller amount of brazzein variants can be used together with a greater amount of other sweeteners such as sucrose, and can be replaced with the other sweeteners. So, the brazzein variants can be widely used as an additive in manufacture of food products.

Abstract: The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a Mycobacteria, for example, Mycobacteria shottsii.

Abstract: The present invention concerns a mixture comprising isoflavones-aglicones, such as daidzein, genistein and glycitein, in addition to equol and lunasin, said mixture being based on soya fermented using lactic acid bacteria isolated from food matrices and use of said mixture for protection of skin and similar and of human intestinal cells with particular reference to prevention of inflammatory state and protection of barrier functions and hair loss treatment.

Abstract: An object is to provide a means of highly producing an oxalate decarboxylase originating in a microorganism. A recombinant expression plasmid vector, which contains an ?-amylase promoter belonging to the genus Bacillus and an oxalate decarboxylase gene originating in a microorganism that is provided under the control of the promoter, is constructed. A host bacterium is transformed with this vector to prepare an oxalate decarboxylase producing bacterium. A recombinant oxalate decarboxylase is produced by culturing the producing bacterium and then recovering the oxalate decarboxylase thus produced.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.

Abstract: An object of the present invention is to find a novel and useful component in a culture supernatant of a lactic acid bacterium and to provide an effective utilization method of the component. The utilization method is a cytoprotective agent containing, as an active ingredient, a low-molecular-weight fraction in a culture supernatant of a lactic acid bacterium belonging to Streptococcus thermophilus.

Abstract: The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to expression of soluble, active recombinant protein by using secretion signals to direct the protein to the periplasmic space of a bacterial cell. In particular, the present invention relates to a production process for obtaining soluble hG-CSF protein from a bacterial host.

Abstract: The present invention provides an innovative versatile system, which allows delivery of one or several antigens or biologically active molecules into or onto targeted subset of cells. The invention is in particular directed to a combination of compounds and in particular to a composition, which comprises: (i) a fusion polypeptide comprising a streptavidin (SA) or avidin polypeptide and one or several effector molecule(s), wherein said fusion polypeptide retains the property of SA and avidin polypeptides to bind biotin; (ii) biotinylated targeting molecule(s), which are capable of targeting subset(s) of cells and/or cell surface molecule(s), and in particular dendritic cells (DC), subsets of DC and/or surface molecule(s) (including surface receptor(s)) of DC.

Abstract: Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.

Abstract: The present invention relates to the preparation of a recombinant polypeptide, which polypeptide upon expression has been secreted into the periplasm of a transformed host cell. In particular, this invention relates to a process to enhance the extraction yield of the recombinant polypeptide from the periplasm before further downstream processing.

Abstract: A method for combining two or more maximum moieties to yield functional cassettes with ultra-high binding affinities, in which at least two binding sequences are incorporated into the same linear polypeptide such that each is separated by between five and forty amino acids, to create a polypeptide having geometrically increased binding affinity compared to the arithmetically summed binding affinities of the individual maximum moieties.

Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g., improved solubility and controlled release characteristics under physiological conditions. Compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects, such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g., bone, cartilage, tendons, ligaments, nerves and skin. These compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.

Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.

Abstract: An expression cassette comprising: a) a bacterial promoter, pZn, containing a binding site for the Lactococcus lactis ZitR protein, which site comprises the following sequence: AAAAATAANGTNNNNNNNTTGACATTATTTTT, (SEQ?ID?NO:?1) in which TTGACA is the ?35 box of said promoter, and N represents A, C, G or T; b) a sequence encoding a polypeptide with at least 80% identity with the Lactococcus lactis ZitR protein, placed under the transcriptional control of said promoter; and wherein the polypeptide is obtained from Lactococcus; and c) at least one restriction site allowing the insertion of a nucleotide sequence of interest under the transcriptional control of said promoter, and wherein the expression cassette does not comprise any part of the sequence encoding the L. lactis ZitS protein.

Abstract: Methods for producing and obtaining natural products from microbial amplification chambers are described. This approach utilizes the concept of green chemistry to synthesize and extract the marine and terrestrial natural products. The method describes techniques to colonize and grow the selected bacteria and to continuously harvest the pharmaceutical agent from the broth without using any commercial solvents.

Abstract: Provided is a method of producing succinic acid in which a microorganism having a succinic acid-producing ability is allowed to react with a sugar, the method being characterized in that the ratio of the oxygen transfer rate to the succinic acid production rate (mmol-O2/mol-SA) is 0.1 to 240 and that the doubling time of the microorganism during the reaction is not shorter than 40 hours.

Abstract: The present invention relates to a method for preparing a casein-derived peptide by fermentation of a lactic acid bacterium. The present invention also relates to a composition containing the peptide, and a method for preparing a functional food.

Abstract: The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing S. aureus strains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.

Abstract: Problem to be Solved: To provide a new microorganism capable of producing a polyhydroxyalkanoate (PHA), a PHA synthase gene, an expression cassette including the gene, a vector including the expression cassette, a transformant transformed by the vector, a polypeptide having PHA synthase activity, a method for producing a PHA synthase and a method for producing a PHA. Solution: The new microorganism is capable of producing a polyhydroxyalkanoate comprising a 16S rRNA gene whose polynucleotide sequence shows 99% or more homology to a polynucleotide sequence represented by SEQ ID No: 1, having an optimum temperature of an activity temperature range for the growth and PHA production of the microorganism of at least 45° C. and being capable of growing at a pH range from 6 to 10.

Abstract: A method of producing an ?-L-aspartyl-L-phenylalanine-?-ester by forming the ?-L-aspartyl-L-phenylalanine-?-ester from L-aspartic acid-?,?-diester and L-phenylalanine using an enzyme or enzyme-containing substance that has an ability to selectively link L-phenylalanine to an ?-ester site of the L-aspartic acid-?,?-diester through a peptide bond.

Abstract: The present invention discloses a process for the preparation of rhPTH (1-34) also known as teriparatide by construction of a novel nucleotide, as an NcoI.IXhoI fragment as set forth in SEQ. ID. No.:1 encoding a chimeric fusion protein as set forth in SEQ.ID. No.:2 comprising of a fusion partner consisting of 41 amino acids belonging to Escherichia coli ?-galactosidase (LacZ) gene, an endopeptidase cleavage site, rhPTH (1-34) gene fragment, cloning the said nucleotide in an expression vector under the control of T7 promoter, transforming Escherichia coli with the said vector and expressing the chimeric fusion protein in fed batch fermentation. The present invention further discloses a low feed rate lactose induction for optimized expression of rhPTH (1-34) in Escherichia coli.

Abstract: A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis.

Abstract: The present invention relates to a novel microorganism producing L-type poly-gamma-glutamic acid and an L-type poly-gamma-glutamic acid produced thereby and, more particularly, to Bacillus megaterium Toha (KCTC11752BP) isolated from salt-fermented Toha shrimps (Korean traditional fermented food) and an L-type poly-gamma-glutamic acid produced thereby. The novel microorganism Bacillus megaterium Toha (KCTC11752BP) has the ability to produce L-type poly-gamma-glutamic acid which can be used in high-value-added microbial agents, probiotic agents, immune-activating agents, animal drugs, cosmetics, moisture absorbers, thickeners, biodegradable plastics, etc.

Abstract: A septum is positioned within a disposable vessel and defines a lower chamber and an upper chamber. The septum includes a plurality of apertures that provide fluid communication between the upper chamber and lower chamber. Compressed gas is introduced in the lower chamber to produce fine bubbles rising up throughout the vessel to produce a mixing and gasification needed for the growth of a biological culture and manufacture of a biological product in a nutrient medium. Adding a binding resin to the upper chamber allows harvesting, separation and purification of biological products in the reactor as a single unit operation.

Abstract: The present invention relates to the preparation and use of variants of the group 1 allergens of the Poaceae (sweet grasses) which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially maintained reactivity with T-lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventive immunotherapy of grass pollen allergies.

Abstract: The present invention provides a process for producing a dipeptide or a dipeptide derivative using a phosphate donor, a substance selected from the group consisting of adenosine-5?-monophosphate, adenosine-5?-diphosphate and adenosine-5?-triphosphate, one or more kinds of amino acids or amino acid derivatives, and as enzyme sources, a protein having polyphosphate kinase activity, or a culture of cells having the ability to produce the protein or a treated matter of the culture, and a protein having the activity to ATP-dependently form the dipeptide or dipeptide derivative from one or more kinds of amino acids or amino acid derivatives, or a culture of cells having the ability to produce the protein or a treated matter of the culture.

Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.

Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.

Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.

Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.

Abstract: A method for the manufacture of products by biotechnological methods in bacterial cell culture is disclosed as well as products obtained, the use of certain additives to the media used in the manufacture of said products in bacterial cell culture media, and the use of said additives in reducing the detrimental effects of radicals in the manufacture of the products, as well as aspects related to these invention embodiments. The manufacturing process or method comprises adding one or more radical scavenging and/or antioxidative additive preferably selected from the group consisting of sterically hindered nitroxyls, sterically hindered hydroxylamines, sterically hindered hydroxylamine salt compounds, sterically hindered amino compounds and sterically hindered N-hydrocarbyloxyamines, benzofuranone compounds, as obligatory component(s) to the medium used during biosynthesis.

Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compostions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Abstract: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.

Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).

Abstract: This invention relates to an aeration system comprising an aeration section, a degassing section and optionally an additional section. This invention also relates to a horizontal photobioreactor comprising the aeration system. This invention further relates to methods of using the photobioreactors.

Abstract: The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described.

Abstract: The present invention relates to Bacillus licheniformis B1 strain, alkalophilic enzyme solution and a method for preparing the same, in particular the method for producing cellulase demonstrating optimal activity at pH 10-13 by using Bacillus licheniformis B1 strain. The enzyme produced by the method of the present invention and the enzyme solution containing the same have excellent enzyme activity in alkali condition, so that they can be effectively applied in diverse uses including the production of detergent or bio-fuel.

Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.

Abstract: The present invention is drawn to a live, attenuated S. Paratyphi A strain, a live, attenuated S. Paratyphi A strain comprising a stabilized plasmid expression system, an S. Paratyphi conjugate vaccine, and methods of using these strains and conjugate vaccine.

Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

Abstract: A method of producing an ?-L-aspartyl-L-phenylalanine-?-ester by forming the ?-L-aspartyl-L-phenylalanine-?-ester from L-aspartic acid-?,?-diester and L-phenylalanine using an enzyme or enzyme-containing substance that has an ability to selectively link L-phenylalanine to an ?-ester site of the L-aspartic acid-?,?-diester through a peptide bond.

Abstract: Described is a DNA molecule comprising an open reading frame sequence that encodes a selectable marker polypeptide, wherein the DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG start codon or a TTG start codon, and wherein the ORF sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native ORF sequence that encodes the selectable marker protein. Further provided are such DNA molecules wherein the ORF sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. Also described are methods for obtaining host cells expressing a polypeptide of interest, wherein the host cells comprise the DNA molecules described herein.

Abstract: The present invention relates to the use of nucleic acid sequences for regulating the transcription and expression of genes, the novel promoters and expression units themselves, methods for altering or causing the transcription rate and/or expression rate of genes, expression cassettes comprising the expression units, genetically modified microorganisms with altered or caused transcription rate and/or expression rate, and methods for preparing biosynthetic products by cultivating the genetically modified microorganisms.

Abstract: An exclusive manufacturing technique for extracting active interface saponin and organic substances from soapberry; organic elements and oleic alcohol products from soapberry seeds through the process of fermentation and end products made therefrom, wherein the manufacturing process includes: 1. Pre-ferment soapberry fruit (1). 2. Processing said fruit (1) by a dialysis device (2). 3. Separating the soapberry flesh (12) and fiber (13) by a separation device (3). 4. Extracting soapberry dialytic liquid (A) through a grinding and compression device (4) and separating the fiber (13). 5. Eliminating bacteria inside the dialytic liquid (A) by a huge stewing device (5). 6. A second fermenting process by a vacuum device (6) and generating a soapberry syrup (D). Said method is healthy, toxin free and biologically safe, produce no wastage, zero carbon emissions, zero pollution, low energy production and is ecologically friendly. End products produced by said method are variables with excellent economic viability.